clinical trial · NCT04580745
Study of MORF 057 to Evaluate Single and Multi Ascending Doses in Healthy Volunteers
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)·phase1·completed·n = 67
Healthy VolunteersMORF-057Placebo for MORF-057
brief summary
Phase 1a randomized, double-blind, placebo-controlled study to evaluate single and multiple ascending doses of MORF-057 in healthy subjects.
started
Sep 23, 2020
primary completion
Mar 31, 2021
completion
Apr 12, 2021
last updated
Aug 1, 2025
official title
A Phase 1a Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Oral MORF-057 in Healthy Subjects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol